Ignite Creation Date:
2025-12-25 @ 1:44 AM
Ignite Modification Date:
2026-02-26 @ 4:18 PM
Study NCT ID:
NCT05422794
Status:
RECRUITING
Last Update Posted:
2025-10-27
First Post:
2022-06-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-18
Start Date Type:
ACTUAL
Primary Completion Date:
2027-03-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-16
First Submit QC Date:
None
Study First Post Date:
2022-06-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-24
Last Update Post Date:
2025-10-27
Last Update Post Date Type:
ESTIMATED